Harmony Biosciences (HRMY) Tops Q3 EPS by 34c ; Offers Guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $1.08, $0.34 better than the analyst estimate of $0.74. Revenue for the quarter came in at $239.5 million versus the consensus estimate of $220.04 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $845-865 million, versus the consensus of $860.5 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• Eagle Plains and Xcite Define Prospective Geophysical Trends at Don Lake and Smitty Uranium Projects, SK
• Goldman Sachs Upgrades Primoris Services Corporation (PRIM) to Neutral